The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing.

The purpose of this acquisition is to purchase Dengue, Chik, and Zika Antigen mixes. Inbios International, Inc. is the only responsible source capable of meeting the Government's requirement because they are the only vendor that can manufacture these FDA approved ELISA reagents. CDC diagnostic procedures require these reagents. The use of any other reagents will compromise the results of current CDC processes. Thus, Inbios International, Inc., the manufacturer of these reagents, is the only company that can be used.

As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to Inbios International, Inc. However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contracting Officer by March 4, 2017. The Contracting Officer will not respond to verbal request. All requests must be in writing.

A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall be sent to Liubov Kriel by email at [email protected] and reference solicitation number 2017-Q-66378 on the subject line.